Cancer Dependency Map Analytics
Cancer, Ageing and Somatic Mutation
In partnership with Open Targets, we provide computational support and analytic solutions to the international Cancer Dependency Map consortium, and to other projects engaged in the analysis of data from large-scale chemo/genetic screens.
Dr Francesco Iorio
Principal Staff Scientist
Francesco is responsible for the design of analytical methods and software, and the management of day-by-day operations to deliver scientific milestones toward the definition of a global Cancer Dependency Map: an atlas of genetic dependencies and vulnerabilities, at an individual cancer cell resolution, which could be exploited for the development of cancer targeted and personalized therapies.
Previous team members
Experimental Cancer Genetics
We are a team of cancer biologists, geneticists and computational biologists interested in understanding how cancers develop and the ways of ...
Translational Cancer Genomics
The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.
We work with the following groups
Open Targets is a pioneering public-private partnership between Biogen, Celgene, EMBL-EBI, GlaxoSmithKline (GSK), Takeda, and the Wellcome Sanger Institute and is located on the Wellcome Genome Campus. Open Targets brings together expertise from six complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed, to help others find good targets, and to get those targets adopted into drug discovery pipelines.Current focuses are oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease.